Compare Salesforce Inc (CRM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs TG Therapeutics Inc — how do they compare? Salesforce Inc trades at $167.39 (market cap $137.23B), while TG Therapeutics Inc trades at $56.13 (market cap $8.41B). The key difference: Salesforce Inc is far larger — about 16.3× TG Therapeutics Inc's market cap, and Salesforce Inc pays a 1.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CRM | TGTX | |
|---|---|---|
Market Cap | $137.23B | $8.41B |
Sector | Technology | Health |
52-Week High | $270.25 | $59.06 |
52-Week Low | $150.12 | $26.39 |
Enterprise Value | $167.28B | $8.65B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.70, down 2.06% amid broader software sector weakness. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.6% gross margin). Technical indicators are neutral with support at $165 and resistance at $171. Recent AI-driven growth initiatives, including Agentforce reaching $2.9B ARR, position the company for continued expansion despite current market pressures.
CRM presents a compelling long-term opportunity with 76.8% analyst buy ratings and a $235.90 consensus target (40% upside). Risks include sector volatility from AI competition and macroeconomic headwinds, but strong cash flow generation ($13.1B operating cash flow in 2025) and market leadership support the bullish case for patient investors.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
